Drug Profile
Pozelimab - Regeneron Pharmaceuticals
Alternative Names: Pozelimab-bbfg; REGN 3918; VeopozLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Protein-losing enteropathy
- Phase III Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(Combination therapy, In volunteers) in Belgium (SC)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(In volunteers) in Belgium (SC)
- 09 Dec 2023 Updated efficacy and adverse event data from a phase II trial in Paroxysmal nocturnal hemoglobinuria presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)